Press releases
GeNeuro Announces Approval of all Resolutions Proposed at 2021 Annual General Meeting
Geneva, Switzerland, June 1, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of May 27, 2021. These included among others:
Availability of documents and information for the annual shareholders’ meeting of May 27, 2021
Geneva, Switzerland, May 6, 2021 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurologic and autoimmune diseases, including multiple sclerosis, informs its shareholders that the Annual General Meeting will be held on Thursday May 27, 2021 at 9.30am at its head office, 3, chemin du Pré-Fleuri, 1228 Plan-lesOuates, Geneva, Switzerland.
https://geneuro.ch/data/news/GeNeuro-2021-AGM-Documents-Availability-EN.pdf
Researchers Detect HERV-W ENV in COVID-19 Patients and Link Expression to Disease Severity
Data published in the Lancet’s EBioMedicine shows that the pathogenic envelope protein of the human endogenous retrovirus W (HERV-W ENV) is found on lymphocytes of hospitalized patients with COVID-19, and that its level of expression is associated with disease severity.
https://geneuro.ch/data/news/GeNeuro-HERV-and-Covid-ENG-April-15-2021.pdf
GeNeuro : financial information for the first quarter 2021
Geneva, Switzerland, April 9, 2021 – 6.00pm CEST
Strong financial situation and visibility:
- Net cash position of €4.8 million
- Debt free
- Company’s operations funded until Q2-2022
GeNeuro Reports 2020 Full-Year Results and Provides Corporate Update
Geneva, Switzerland, April 6, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a clinical-stage biopharmaceutical company leveraging the biology of human endogenous retroviruses (HERVs) to develop new treatments to stop the progression of neurodegenerative and autoimmune diseases, reported today its full-year results for the year ended December 31, 2020 and provided a corporate update
https://geneuro.ch/data/news/2021.04.06-GeNeuro-PR-FYR2020results-EN-vf.pdf
GeNeuro’s temelimab Phase 2 multiple sclerosis trial cleared to continue following planned Data Safety Monitoring Board Meeting
Geneva, Switzerland, March 2, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that the independent Drug Safety Monitoring Board (DSMB) has concluded the Phase 2 trial of temelimab in MS patients should continue as planned without modification. This follows a pre-determined review of the first 8 patients treated with temelimab for 2 months at doses of 18, 36 and 54 mg/kg. The study, called ProTEct-MS, is being conducted at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm (Sweden).
https://geneuro.ch/data/news/GeNeuro-MS-Study-DSMB-Approval-ENG.pdf